ADMA Biologics, Inc.
S&P 600
$9.23
-1.70%
Delayed · cached 15 min
Fair value analysis
ADMA
ADMA Biologics, Inc.
$9.23
Close used for this calculation
$7.04Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
73/100
Quality radar
Consensus fair value
$7.04
Above FV▼ -23.7% against the close used
Model range $2.13 – $15.56
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$2.13Fair value$7.04Bull$15.56
FairClose
52-week traded range
52W low $7.6052W high $20.38
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
ADMA Biologics, Inc. closed at $9.23, 31.1% above the consensus fair value of $7.04 drawn from 7 valuation models.
Financial DNA score 73/100 — Strong. P/E of 15.4x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$2.13
-76.9%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
P/E Fair Value
$12.00
+30.0%
EPS × 20x (sector P/E)
EPS=0.6, Sector P/E=20x
Peter Lynch (PEG)
$15.56
+68.6%
EPS × Growth% (PEG = 1 is fair)
EPS=0.6, g=25.9%
EV/EBITDA
$8.14
-11.8%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=199.44M
Book Value (P/B)
$8.35
-9.5%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=1.77, ROE=36%, g=3%, r=10%
Reverse DCF
$9.23
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 3.6% | Historical: -25.9%
Margin of Safety
$5.30
-42.6%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=7.06, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.